Literature DB >> 18670442

The spectrum and treatment of gastrointestinal disorders during pregnancy.

Jutta Keller1, Dorothea Frederking, Peter Layer.   

Abstract

Gastrointestinal symptoms are extremely common during pregnancy. Increased levels of female sex hormones cause or contribute to symptoms such as heartburn, nausea, vomiting and constipation. If these symptoms do not respond adequately to lifestyle and dietary changes, drug therapy is often warranted to improve quality of life and to prevent complications. Physicians, therefore, need to be familiar with the low-risk treatment options available. Treatment of chronic conditions such as IBD or chronic liver disease during pregnancy can be demanding. In women with IBD, maintenance of adequate disease control during pregnancy is crucial. Most IBD drugs can be used during pregnancy, but the benefits and risks of specific drugs should be discussed with the patient. Liver diseases can be coincidental or pregnancy-specific. Pregnancy-specific liver diseases include not only benign disorders such as intrahepatic cholestasis of pregnancy, but also pre-eclampsia, eclampsia and HELLP syndrome (hemolytic anemia, elevated liver enzymes and low platelet count). Accordingly, the spectrum of therapeutic measures ranges from expectant management to urgent induction of delivery. During pregnancy, lamuvidine therapy for chronic hepatitis B can be continued; however, interferon and ribavirin therapy for chronic hepatitis C is contraindicated. This Review provides an overview of the spectrum and therapy of motility disturbances that occur during pregnancy, and discusses pregnancy-specific aspects of IBD and liver diseases.

Entities:  

Mesh:

Year:  2008        PMID: 18670442     DOI: 10.1038/ncpgasthep1197

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  9 in total

1.  Pelvic organ support, symptoms and quality of life during pregnancy: a prospective study.

Authors:  Ksenia Elenskaia; Ranee Thakar; Abdul H Sultan; Inka Scheer; Joseph Onwude
Journal:  Int Urogynecol J       Date:  2012-09-22       Impact factor: 2.894

2.  Population Scale Retrospective Analysis Reveals Potential Risk of Cholestasis in Pregnant Women Taking Omeprazole, Lansoprazole, and Amoxicillin.

Authors:  Yonghong Zhang; Da Shi; Ruben Abagyan; Weina Dai; Mingyang Dong
Journal:  Interdiscip Sci       Date:  2019-05-20       Impact factor: 2.233

3.  Iron bioavailability from commercially available iron supplements.

Authors:  Tatiana Christides; David Wray; Richard McBride; Rose Fairweather; Paul Sharp
Journal:  Eur J Nutr       Date:  2014-12-20       Impact factor: 5.614

Review 4.  Management of Inflammatory Bowel Disease During Pregnancy.

Authors:  Ariella Bar-Gil Shitrit; Sorina Grisaru-Granovsky; Ami Ben Ya'acov; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-04-11       Impact factor: 3.199

5.  Missed opportunities: Peripartum hepatic failure in a Chinese immigrant.

Authors:  Malika Sharma; Shital Gandhi
Journal:  Obstet Med       Date:  2014-08-15

6.  Enteric neurons and systemic signals couple nutritional and reproductive status with intestinal homeostasis.

Authors:  Paola Cognigni; Andrew P Bailey; Irene Miguel-Aliaga
Journal:  Cell Metab       Date:  2011-01-05       Impact factor: 27.287

Review 7.  Evidence-based treatment recommendations for gastroesophageal reflux disease during pregnancy: A review.

Authors:  Mansour Altuwaijri
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

8.  Endocrine remodelling of the adult intestine sustains reproduction in Drosophila.

Authors:  Tobias Reiff; Jake Jacobson; Paola Cognigni; Zeus Antonello; Esther Ballesta; Kah Junn Tan; Joanne Y Yew; Maria Dominguez; Irene Miguel-Aliaga
Journal:  Elife       Date:  2015-07-28       Impact factor: 8.140

9.  Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.

Authors:  Shannon Linda Kanis; Sanne Modderman; Johanna C Escher; Nicole Erler; Ruud Beukers; Nanne de Boer; Alexander Bodelier; Annekatrien C T M Depla; Gerard Dijkstra; Anne-Baue Ruth Margaretha van Dijk; Lennard Gilissen; Frank Hoentjen; Jeroen M Jansen; Johan Kuyvenhoven; Nofel Mahmmod; Rosalie C Mallant-Hent; Andrea E van der Meulen-de Jong; Anahita Noruzi; Bas Oldenburg; Liekele E Oostenbrug; Pieter C J Ter Borg; Marieke Pierik; Mariëlle Romberg-Camps; Willem Thijs; Rachel West; Alison de Lima; C Janneke van der Woude
Journal:  Gut       Date:  2020-10-12       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.